IMPACT-AML Contributes to the Dialogue at the 5 Years of the EU Cancer Mission Event
IMPACT-AML took part in the “5 Years of the EU Cancer Mission” event in Brussels, joining researchers, clinicians, policymakers, patient representatives, innovators and project teams from across Europe to reflect on the achievements of the Mission and discuss the path ahead in the fight against cancer. The event provided a unique opportunity for the European cancer community to exchange knowledge, share experiences and strengthen collaborations aimed at improving cancer prevention, diagnosis, treatment and quality of life for patients and survivors.
In his opening remarks, Marc Lemaître, Director-General for Research and Innovation at the European Commission, emphasized that the next phase of the EU Cancer Mission will focus on accelerating the delivery of results, scaling up impact and recognizing health innovation as a strategic asset for Europe. This vision closely aligns with the goals of IMPACT-AML, which is committed to advancing innovative research approaches to improve outcomes for patients with acute myeloid leukemia (AML).
Throughout the event, IMPACT-AML had the opportunity to engage with stakeholders and fellow Mission projects, highlighting the importance of collaboration and cross-sector partnerships in translating scientific excellence into tangible benefits for patients and healthcare systems.
Visitors to the IMPACT-AML booth engaged in valuable discussions with project representatives, reinforcing the shared commitment to addressing some of the most pressing challenges in cancer research and care. These exchanges underscored the crucial role of cooperation among researchers, healthcare professionals, institutions and citizens in driving meaningful progress against cancer.
The project was represented by Chiara Zingaretti and Francesco Ghini from IRST IRCCS, together with Gianni D’Errico from Fondazione Toscana Life Sciences, who actively contributed to discussions and networking activities that fostered the exchange of knowledge and strengthened collaboration among leading European stakeholders in the oncology sector.
Participation in initiatives such as the 5 Years of the EU Cancer Mission event strengthens IMPACT-AML’s commitment to the objectives of the European Cancer Mission and to fostering innovation, collaboration and scientific excellence across the cancer research landscape.
By working together with partners across Europe, IMPACT-AML aims to help transform research and innovation into real-world impact, contributing to better outcomes and new opportunities for patients affected by acute myeloid leukemia and other cancers.
